10x Genomics, Inc.
corporate_fare Company Profile
10x Genomics, Inc. (NASDAQ:TXG) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 11 items for TXG at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 11 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for TXG spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- 10x Genomics 10-Q: Q3 Revenue $150.7M, Gross Margin Jumps to 75%, Cash $575.7M
- 10x Genomics Lifts Full-Year Revenue Guidance After Q3 Beat, Atera Ramp Begins
- 10x Genomics Ships First Atera Instruments as Demand Tops 2026 Target
- 10x Genomics Q2 Revenue Drops 13% as Patent Settlement Windfall Fades; New IP Suits Filed
- 10x Genomics Acquires Proteintech Genomics Division
Financial Snapshot
Short Interest & Short Volume
4.13 days to coverFINRA reported short interest of 12,473,112 shares in TXG as of the October 30, 2026 settlement, a 2.0% decrease from the prior period — about 4.1 days to cover at its recent average daily volume. On November 20, 2026, 34.2% of TXG volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.